 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 OVERVIEW About 80% of all malaria deaths occur in Africa south of the Sahara, and the great majority in children under five. The inappropriate use of antimalarial drugs during the past century has contributed to many of these deaths: antimalarial drugs were deployed on a large scale, always as monotherapies and were generally poorly managed in that their use was continued despite unacceptably high levels of resistance. However, over the past decade, a new class of drugs derived from the plant artemisia annua has brought new hopes - artemisinin. When used correctly in combination with other anti-malarial drugs, (Artemisinin-based Combination Therapies - ACTs), artemisinin is nearly 95% effective in curing malaria. |
|
 |
||
|
 |
Support the Global Fund Now. Say Yes to Round 6! Yet access to these more effective but more expensive ACTs will not be achievable without continuous funding from the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) - the largest financier of the global fight against malaria. To date, the GFATM has already allocated - after five funding rounds -,$1.2 billion for programs fighting the disease in more than 60 countries around the world. However, a new round of funding (Round 6) is today jeopardized by the lack of finances available. The Global Fund urgently needs increased contributions from donors to ensure uninterrupted support to countries scaling up malaria control. Africa Malaria Day 2006 therefore offers a strong opportunity to advocate for additional funding for the Global Fund. |
RBM Partners commemorate Africa Malaria Day 2006 GFATM
|
|
||
|
|
|||||